15th Annual Angiogenesis, Exudation, and Degeneration 2018
OVERVIEW
15th Annual Angiogenesis, Exudation, and Degeneration is organized by Bascom Palmer Eye Institute and will be held on Feb 10, 2018 at Mandarin Oriental, Miami, Miami, Florida, United States of America.
The target audience for this medical event is designed for retina specialists, general ophthalmologists and researchers. This CME Conference has been approved for a maximum of 9.5 AMA PRA Category 1 Credits.
Course Description :
The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
The current program will review the latest in translational research and clinical trials with an emphasis on how these results will impact clinical ophthalmology. We will emphasize recently completed studies for treatment of a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions.
Course Objectives are :
• Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases.
• Improve management skills by evaluating all the risks associated with injections of anti-VEGF drugs.
• Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions.
• Analyze results of clinical trials in exudative and non-exudative macular diseases and apply to clinical practice.
• Evaluate the benefits and limitations of combination therapies for exudative macular diseases.
• Evaluate the benefits and limitations of different imaging strategies for macular diseases.
• Evaluate the emerging imaging technology known as OCT angiography.
• Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions.
Additional details will be posted as soon as they are available.
The target audience for this medical event is designed for retina specialists, general ophthalmologists and researchers. This CME Conference has been approved for a maximum of 9.5 AMA PRA Category 1 Credits.
Course Description :
The meeting will highlight the revolutionary pharmacotherapies now in development and clinical practice for the management of neovascular AMD, macular edema, diabetic retinopathy, and retinopathy of prematurity with a special emphasis on the present and future financial impact of these drugs on clinical practices and Medicare.
The current program will review the latest in translational research and clinical trials with an emphasis on how these results will impact clinical ophthalmology. We will emphasize recently completed studies for treatment of a broad spectrum of retinal diseases with special emphasis on age-related macular degeneration, diabetic retinopathy, and retinal vein occlusions.
Course Objectives are :
• Enhance patient care by evaluating the current global use of anti-VEGF drugs for exudative ocular diseases.
• Improve management skills by evaluating all the risks associated with injections of anti-VEGF drugs.
• Analyze the rationale for emerging treatments for different macular and retinal degenerative conditions.
• Analyze results of clinical trials in exudative and non-exudative macular diseases and apply to clinical practice.
• Evaluate the benefits and limitations of combination therapies for exudative macular diseases.
• Evaluate the benefits and limitations of different imaging strategies for macular diseases.
• Evaluate the emerging imaging technology known as OCT angiography.
• Enhance patient care by analyzing the genetic basis for different macular and retinal degenerative conditions.
Additional details will be posted as soon as they are available.
KEY DATES
10 Feb, 2018
Event Start Date
10 Feb, 2018
Event End Date
SPECIALITIES
OphthalmologySUGGESTED HOTELS
CONFERENCE VENUE
Mandarin Oriental, MiamiQuick Links